TY - JOUR
T1 - Magnetic drug delivery with FePd nanowires
AU - Pondman, Kirsten M.
AU - Bunt, Nathan D.
AU - Maijenburg, A. Wouter
AU - van Wezel, Richard J.A.
AU - Kishore, Uday
AU - Abelmann, Leon
AU - ten Elshof, Johan E.
AU - ten Haken, Bennie
N1 - Publisher Copyright:
© 2014 Elsevier B.V. All rights reserved.
PY - 2015/4/15
Y1 - 2015/4/15
N2 - Magnetic drug delivery is a promising method to target a drug to a diseased area while reducing negative side effects caused by systemic administration of drugs. In magnetic drug delivery a therapeutic agent is coupled to a magnetic nanoparticle. The particles are injected and at the target location withdrawn from blood flow by a magnetic field. In this study a FePd nanowire is developed with optimised properties for magnetic targeting. The nanowires have a high magnetic moment to reduce the field gradient needed to capture them with a magnet. The dimensions and the materials of the nanowire and coating are such that they are dispersable in aqueous media, non-cytotoxic, easily phagocytosed and not complement activating. This is established in several in-vitro tests with macrophage and endothelial cell lines. Along with the nanowires a magnet is designed, optimised for capture of the nanowires from the blood flow in the hind leg of a rat. The system is used in a pilot scale in-vivo experiment. No negative side effects from injection of the nanowires were found within the limited time span of the experiment. In this first pilot experiment no nanowires were found to be targeted by the magnet, or in the liver, kidneys or spleen, most likely the particles were removed during the fixation procedure.
AB - Magnetic drug delivery is a promising method to target a drug to a diseased area while reducing negative side effects caused by systemic administration of drugs. In magnetic drug delivery a therapeutic agent is coupled to a magnetic nanoparticle. The particles are injected and at the target location withdrawn from blood flow by a magnetic field. In this study a FePd nanowire is developed with optimised properties for magnetic targeting. The nanowires have a high magnetic moment to reduce the field gradient needed to capture them with a magnet. The dimensions and the materials of the nanowire and coating are such that they are dispersable in aqueous media, non-cytotoxic, easily phagocytosed and not complement activating. This is established in several in-vitro tests with macrophage and endothelial cell lines. Along with the nanowires a magnet is designed, optimised for capture of the nanowires from the blood flow in the hind leg of a rat. The system is used in a pilot scale in-vivo experiment. No negative side effects from injection of the nanowires were found within the limited time span of the experiment. In this first pilot experiment no nanowires were found to be targeted by the magnet, or in the liver, kidneys or spleen, most likely the particles were removed during the fixation procedure.
KW - Immune response
KW - Magnetic drug delivery
KW - Nanowire
KW - Toxicity
KW - 2023 OA procedure
UR - http://www.scopus.com/inward/record.url?scp=85027952112&partnerID=8YFLogxK
U2 - 10.1016/j.jmmm.2014.10.101
DO - 10.1016/j.jmmm.2014.10.101
M3 - Article
SN - 0304-8853
VL - 380
SP - 299
EP - 306
JO - Journal of magnetism and magnetic materials
JF - Journal of magnetism and magnetic materials
ER -